Wyszuk.
zaawans.

Version of Record
Wytyczne / stanowisko ekspertów
Opublikowany online: 2025-08-12
Dodaj do koszyka: 95,00 PLN
Wyświetlenia strony 470
Wyświetlenia/pobrania artykułu 39
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Facebook X LinkedIn Share

Zalecenia Polskiego Towarzystwa Ginekologii Onkologicznej dotyczące diagnostyki i leczenia raka jajnika (2025)

Anita Chudecka-Głaz1, Mariusz Bidziński2, Lubomir Bodnar3, Anna Dańska-Bidzińska2, Paweł Blecharz2, Artur Kowalik45, Paweł Knapp6, Maciej Stukan7, Marcin Misiek8, Rafał Stojko9, Radosław Mądry10, Magdalena Kowalska2, Laretta Grabowska-Derlatka11, Alekandra Zielińska12, Janusz Ryś13, Paweł Basta1415, Małgorzata Witkowska16, Magdalena Łasińska-Kowara17, Karol Boniecki16, Włodzimierz Sawicki12

Streszczenie

Jednym z podstawowych zadań towarzystw naukowych jest tworzenie nowoczesnych zaleceń, których celem jest ujednolicenie oraz poprawa wyników leczenia chorych. Dlatego też Polskie Towarzystwo Ginekologii Onkologicznej podjęło się opracowania wytycznych dotyczących diagnostyki i leczenia chorych na raka jajnika. Zalecenia zostały opracowane na podstawie analizy metodologii zidentyfikowanych dowodów naukowych dotyczących diagnozowania, leczenia i obserwacji po leczeniu raka jajnika, wykorzystując metodę Appraisal of Guidelines for Research and Evaluation (AGREE) II — narzędzie do oceny wytycznych. Siłę poszczególnych dowodów naukowych zdefiniowano zgodnie z kryteriami opisanymi przez Agencję Oceny Technologii Medycznych i Taryfikacji (AOTMiT). Zalecenia przeznaczone są dla lekarzy praktyków zajmujących się leczeniem chorych na raka jajnika. 

Słowa kluczowe: rak jajnikadiagnostyka molekularnadiagnostyka obrazowachirurgiarekomendacje

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 95,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Wojciechowska U, Didkowska J, Barańska K, et al. Nowotwory złośliwe w Polsce w 2022 roku. Ministerstwo Zdrowia, Warszawa 2024.
  2. Brouwers MC, Kho ME, Browman GP, et al. AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18): E839–E842.
    CrossRefPubMed
  3. Rychert A, Krasztel M, Sejbuk-Rozbicka K, et al. Systemy klasyfikacji światowych zaleceń postępowania diagnostyczno-terapeutycznego na przykładzie wytycznych onkologicznych. Wydział Świadczeń Opieki Zdrowotnej , Agencja Oceny Technologii Medycznych i Taryfikacji, Warszawa 2018.
  4. WHO Classification of Tumors. Editorial Board. Female Genital Tumors, 5th ed. WHO classification of Tumors Series, volume 14. International Agency of Research on Cancer, Lyon 2020.
  5. Santandrea G, Piana S, Valli R, et al. Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. Diagnostics (Basel). 2021; 11(2).
    CrossRefPubMed
  6. Buza N. Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Semin Diagn Pathol. 2022; 39(1): 58–77.
    CrossRefPubMed
  7. Köbel M, Kang EY. The Evolution of Ovarian Carcinoma Subclassification. Cancers (Basel). 2022; 14(2).
    CrossRefPubMed
  8. Kowalik A, Zalewski K, Kopczyński J, et al. Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. Pol J Pathol. 2019; 70(2): 115–126.
    CrossRefPubMed
  9. Chandrasekaran D, Sobocan M, Blyuss O, et al. Implementation of Multigene Germline and Parallel Somatic Genetic Testing in Epithelial Ovarian Cancer: SIGNPOST Study. Cancers (Basel). 2021; 13(17).
    CrossRefPubMed
  10. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20(3): 764–775.
    CrossRefPubMed
  11. Candido-dos-Reis F, Song H, Goode E, et al. Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clin Cancer Res. 2015; 21(3): 652–657.
    CrossRefPubMed
  12. Gronwald J, Huzarski T, Byrski B, et al. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet. 2006; 43(5): 424–428.
    CrossRefPubMed
  13. Antoniou AC, Pharoah PDP, Narod S, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet. 2005; 42(7): 602–603.
    CrossRefPubMed
  14. Wong W, Raufi A, Safyan R, et al. BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects. Cancer Manag Res. 2020; 12: 2731–2742.
    CrossRefPubMed
  15. Fumagalli C, Betella I, Ranghiero A, et al. In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay. Pathologica. 2022; 114(4): 288–294.
    CrossRefPubMed
  16. Magliacane G, Brunetto E, Calzavara S, et al. Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can! Cancers (Basel). 2022; 15(1).
    CrossRefPubMed
  17. Weichert W, Qiu P, Lunceford J, et al. Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit. J Clin Oncol. 2022; 40(16_suppl): e17571–e17571.
    CrossRef
  18. Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020; 31(12): 1606–1622.
    CrossRefPubMed
  19. Langfort R, Marszałek A, Ryś J. Wytyczne dla zakładów/pracowni patomorfologii. Standardy organizacyjne oraz standardy postępowania w patomorfologii 2020. https://zdrowie.gov.pl/uploads/pub/pages/page_1053/text_images/standardy_patomorfologia.pdf.
  20. Capoluongo E, Ellison G, López-Guerrero JA, et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin Oncol. 2017; 44(3): 187–197.
    CrossRefPubMed
  21. Grafodatskaya D, O’Rielly D, Bedard K, et al. Practice guidelines for BRCA1/2 tumour testing in ovarian cancer. J Med Genet. 2022; 59(8): 727–736.
    CrossRefPubMed
  22. den Dunnen JT, Dalgleish R, Maglott DR, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016; 37(6): 564–569.
    CrossRefPubMed
  23. Hennessy BTJ, Timms KM, Carey MS, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010; 28(22): 3570–3576.
    CrossRefPubMed
  24. Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397(10290): 2182–2193.
    CrossRefPubMed
  25. Rosenthal AN, Fraser LSM, Philpott S, et al. United Kingdom Familial Ovarian Cancer Screening Study collaborators. Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol. 2017; 35(13): 1411–1420.
    CrossRefPubMed
  26. Kaijser J, Vandecaveye V, Deroose CM, et al. Imaging techniques for the pre-surgical diagnosis of adnexal tumours. Best Pract Res Clin Obstet Gynaecol. 2014; 28(5): 683–695.
    CrossRefPubMed
  27. Valentin L, Hagen B, Tingulstad S, et al. Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol. 2001; 18(4): 357–365.
    CrossRefPubMed
  28. Meys EMJ, Kaijser J, Kruitwagen RF, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer. 2016; 58: 17–29.
    CrossRefPubMed
  29. Yazbek J, Raju SK, Ben-Nagi J, et al. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. Lancet Oncol. 2008; 9(2): 124–131.
    CrossRefPubMed
  30. Timmerman D, Planchamp F, Bourne T, et al. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int J Gynecol Cancer. 2021; 31(7): 961–982.
    CrossRefPubMed
  31. Landolfo C, Bourne T, Froyman W, et al. Benign descriptors and ADNEX in two-step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort. Ultrasound Obstet Gynecol. 2023; 61(2): 231–242.
    CrossRefPubMed
  32. Medeiros LR, Rosa DD, da Rosa MI, et al. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009; 142(2): 99–105.
    CrossRefPubMed
  33. Van Calster B, Valentin L, Froyman W, et al. Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study. BMJ. 2020; 370: m2614.
    CrossRefPubMed
  34. Van Calster B, Van Hoorde K, Valentin L, et al. International Ovarian Tumour Analysis Group. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ. 2014; 349: g5920.
    CrossRefPubMed
  35. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010; 203(3): 228.e1–228.e6.
    CrossRefPubMed
  36. Dolgun ZN, Kabaca C, Karateke A, et al. The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses. Balkan Med J. 2017; 34(2): 156–162.
    CrossRefPubMed
  37. Piovano E, Cavallero C, Fuso L, et al. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study. Ultrasound Obstet Gynecol. 2017; 50(3): 395–403.
    CrossRefPubMed
  38. Lycke M, Kristjansdottir B, Sundfeldt K. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1): 159–165.
    CrossRefPubMed
  39. Wang WH, Zheng CB, Gao JN, et al. Systematic review and meta-analysis of imaging differential diagnosis of benign and malignant ovarian tumors. Gland Surg. 2022; 11(2): 330–340.
    CrossRefPubMed
  40. Rizzo S, Cozzi A, Dolciami M, et al. O-RADS MRI: A Systematic Review and Meta-Analysis of Diagnostic Performance and Category-wise Malignancy Rates. Radiology. 2023; 307(1): e220795.
    CrossRefPubMed
  41. Hu X, Li D, Liang Z, et al. Indirect comparison of the diagnostic performance of F-FDG PET/CT and MRI in differentiating benign and malignant ovarian or adnexal tumors: a systematic review and meta-analysis. BMC Cancer. 2021; 21(1): 1080.
    CrossRefPubMed
  42. Taylor EC, Irshaid L, Mathur M. Multimodality Imaging Approach to Ovarian Neoplasms with Pathologic Correlation. Radiographics. 2021; 41(1): 289–315.
    CrossRefPubMed
  43. Derlatka P, Grabowska-Derlatka L, Halaburda-Rola M, et al. The Value of Magnetic Resonance Diffusion-Weighted Imaging and Dynamic Contrast Enhancement in the Diagnosis and Prognosis of Treatment Response in Patients with Epithelial Serous Ovarian Cancer. Cancers (Basel). 2022; 14(10).
    CrossRefPubMed
  44. Jian J, Li Y, Pickhardt PJ, et al. MR image-based radiomics to differentiate type Ι and type ΙΙ epithelial ovarian cancers. Eur Radiol. 2021; 31(1): 403–410.
    CrossRefPubMed
  45. Gadelhak B, Tawfik AM, Saleh GA, et al. Extended abdominopelvic MRI versus CT at the time of adnexal mass characterization for assessing radiologic peritoneal cancer index (PCI) prior to cytoreductive surgery. Abdom Radiol (NY). 2019; 44(6): 2254–2261.
    CrossRefPubMed
  46. Dohan A, Hoeffel C, Soyer P, et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br J Surg. 2017; 104(9): 1244–1249.
    CrossRefPubMed
  47. Shim SH, Lee SJ, Kim SO, et al. Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients. Gynecol Oncol. 2015; 136(1): 30–36.
    CrossRefPubMed
  48. Gemer O, Gdalevich M, Ravid M, et al. A multicenter validation of computerized tomography models as predictors of non- optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol. 2009; 35(10): 1109–1112.
    CrossRefPubMed
  49. Rutten MJ, van de Vrie R, Bruining A, et al. Predicting surgical outcome in patients with International Federation of Gynecology and Obstetrics stage III or IV ovarian cancer using computed tomography: a systematic review of prediction models. Int J Gynecol Cancer. 2015; 25(3): 407–415.
    CrossRefPubMed
  50. Testa A, Kaijser J, Wynants L, et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. Br J Cancer. 2014; 111(4): 680–688.
    CrossRefPubMed
  51. Lindgren A, Anttila M, Arponen O, et al. Prognostic value of preoperative dynamic contrast-enhanced magnetic resonance imaging in epithelial ovarian cancer. Eur J Radiol. 2019; 115: 66–73.
    CrossRefPubMed
  52. Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020; 30(11): 1657–1664.
    CrossRefPubMed
  53. Fagotti A, Ferrandina G, Vizzielli G, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. Eur J Cancer. 2016; 59: 22–33.
    CrossRefPubMed
  54. Trelis Blanes A, Lago Leal V, Padilla Iserte P, et al. Optimal cytoreduction: is a CT's picture worth a surgeon's word? Surg Oncol. 2023; 49: 101948.
    CrossRefPubMed
  55. Bregar A, Mojtahed A, Kilcoyne A, et al. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. Gynecol Oncol. 2019; 152(3): 568–573.
    CrossRefPubMed
  56. Morgan RD, McNeish IA, Cook AD, et al. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 2021; 22(2): 277–288.
    CrossRefPubMed
  57. Cohen PA, Powell A, Böhm S, et al. HGSC CRS Collaborative Network (Supplementary 1). Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecol Oncol. 2019; 152(2): 441–448.
    CrossRefPubMed
  58. Rustin GJS, van der Burg MEL, Griffin CL, et al. MRC OV05, EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010; 376(9747): 1155–1163.
    CrossRefPubMed
  59. Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M, et al. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? PLoS One. 2018; 13(3): e0194270.
    CrossRefPubMed
  60. Rustin GJ, Vergote I, Eisenhauer E, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011; 21(2): 419–423.
    CrossRefPubMed
  61. Faubion SS, MacLaughlin KL, Long ME, et al. Surveillance and Care of the Gynecologic Cancer Survivor. J Womens Health (Larchmt). 2015; 24(11): 899–906.
    CrossRefPubMed
  62. Clarke T, Galaal K, Bryant A, et al. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane Database Syst Rev. 2014; 2014(9): CD006119.
    CrossRefPubMed
  63. Morrison V, Spencer LH, Totton N, et al. Trial of Optimal Personalised Care After Treatment-Gynaecological Cancer (TOPCAT-G): A Randomized Feasibility Trial. Int J Gynecol Cancer. 2018; 28(2): 401–411.
    CrossRefPubMed
  64. Lanceley A, Berzuini C, Burnell M, et al. Ovarian Cancer Follow-up: A Preliminary Comparison of 2 Approaches. Int J Gynecol Cancer. 2017; 27(1): 59–68.
    CrossRefPubMed
  65. Fidjeland HL, Brekke M, Stokstad T, et al. General practitioners' attitudes toward follow-up after cancer treatment: A cross-sectional questionnaire study. Scand J Prim Health Care. 2015; 33(4): 223–232.
    CrossRefPubMed
  66. Manganaro L, Gigli S, Antonelli A, et al. Imaging strategy in recurrent ovarian cancer: a practical review. Abdom Radiol (NY). 2019; 44(3): 1091–1102.
    CrossRefPubMed
  67. Skírnisdóttir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008; 123(8): 1897–1901.
    CrossRefPubMed
  68. Sherman ME, Berman J, Birrer MJ, et al. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol. 2004; 35(8): 961–970.
    CrossRefPubMed
  69. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the Ovary. Int J Gynaecol Obstet. 2006; 95 Suppl 1: S161–S192.
    CrossRefPubMed
  70. Morice P. Borderline tumours of the ovary and fertility. Eur J Cancer. 2006; 42(2): 149–158.
    CrossRefPubMed
  71. Tropé C, Davidson B, Paulsen T, et al. Diagnosis and treatment of borderline ovarian neoplasms ‘the state of the art’. Eur J Gynaecol Oncol. 2009; 30(5): 471–482.
    PubMed
  72. Palomba S, Falbo A, Del Negro S, et al. Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up. Hum Reprod. 2010; 25(8): 1966–1972.
    CrossRefPubMed
  73. Poncelet C, Fauvet R, Boccara J, et al. Recurrence after cystectomy for borderline ovarian tumors: results of a French multicenter study. Ann Surg Oncol. 2006; 13(4): 565–571.
    CrossRefPubMed
  74. Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases. Obstet Gynecol. 1988; 72(5): 775–781.
    PubMed
  75. Johansen G, Dahm-Kähler P, Staf C, et al. Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. Fertil Steril. 2021; 115(1): 157–163.
    CrossRefPubMed
  76. Tempfer CB, Polterauer S, Bentz EK, et al. Accuracy of intraoperative frozen section analysis in borderline tumors of the ovary: a retrospective analysis of 96 cases and review of the literature. Gynecol Oncol. 2007; 107(2): 248–252.
    CrossRefPubMed
  77. Zapardiel I, Rosenberg P, Peiretti M, et al. The role of restaging borderline ovarian tumors: single institution experience and review of the literature. Gynecol Oncol. 2010; 119(2): 274–277.
    CrossRefPubMed
  78. Chevrot A, Héquet D, Fauconnier A, et al. Impact of surgical restaging on recurrence in patients with borderline ovarian tumors: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2020; 248: 227–232.
    CrossRefPubMed
  79. Camatte S, Morice P, Thoury A, et al. Impact of surgical staging in patients with macroscopic "stage I" ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004; 40(12): 1842–1849.
    CrossRefPubMed
  80. Fauvet R, Boccara J, Dufournet C, et al. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer. 2004; 100(6): 1145–1151.
    CrossRefPubMed
  81. Trillsch F, Mahner S, Vettorazzi E, et al. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer. 2015; 112(4): 660–666.
    CrossRefPubMed
  82. Kane A, Uzan C, Rey A, et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist. 2009; 14(6): 591–600.
    CrossRefPubMed
  83. Helpman L, Beiner ME, Aviel-Ronen S, et al. Safety of ovarian conservation and fertility preservation in advanced borderline ovarian tumors. Fertil Steril. 2015; 104(1): 138–144.
    CrossRefPubMed
  84. Huang Y, Zhang W, Wang Y. The feasibility of fertility-sparing surgery in treating advanced-stage borderline ovarian tumors: A meta-analysis. Taiwan J Obstet Gynecol. 2016; 55(3): 319–325.
    CrossRefPubMed
  85. Ratnavelu NDG, Brown AP, Mallett S, et al. Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses. Cochrane Database Syst Rev. 2016; 3(3): CD010360.
    CrossRefPubMed
  86. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001; 19(10): 2658–2664.
    CrossRefPubMed
  87. Trillsch F, Mahner S, Vettorazzi E, et al. Surgical staging and prognosis in serous borderline ovarian tumours (BOT): a subanalysis of the AGO ROBOT study. Br J Cancer. 2015; 112(4): 660–666.
    CrossRefPubMed
  88. Vasconcelos I, de Sousa Mendes M. Conservative surgery in ovarian borderline tumours: a meta-analysis with emphasis on recurrence risk. Eur J Cancer. 2015; 51(5): 620–631.
    CrossRefPubMed
  89. Jia SZ, Zhang JJ, Liang ZY, et al. Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours. BMC Cancer. 2018; 18(1): 1160.
    CrossRefPubMed
  90. Raimondo D, Raffone A, Zakhari A, et al. The impact of hysterectomy on oncological outcomes in patients with borderline ovarian tumors: A systematic review and meta-analysis. Gynecol Oncol. 2022; 165(1): 184–191.
    CrossRefPubMed
  91. Fan Yu, Zhang YF, Wang MY, et al. Influence of lymph node involvement or lymphadenectomy on prognosis of patients with borderline ovarian tumors: A systematic review and meta-analysis. Gynecol Oncol. 2021; 162(3): 797–803.
    CrossRefPubMed
  92. Cheng A, Li M, Kanis MJ, et al. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis. Gynecol Oncol. 2017; 144(1): 215–222.
    CrossRefPubMed
  93. Tang M, O'Connell RL, Amant F, et al. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecol Oncol. 2019; 154(3): 531–538.
    CrossRefPubMed
  94. Jiao X, Hu J, Zhu L. Prognostic Factors for Recurrence After Fertility-Preserving Surgery in Patients With Borderline Ovarian Tumors: A Systematic Review and Meta-analysis of Observational Studies. Int J Gynecol Cancer. 2017; 27(9): 1833–1841.
    CrossRefPubMed
  95. Gershenson DM, Sun CC, Lu KH, et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006; 108(2): 361–368.
    CrossRefPubMed
  96. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004; 28(4): 496–504.
    CrossRefPubMed
  97. Cobb L, Sun C, Iyer R, et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol. 2020; 158(3): 653–658.
    CrossRefPubMed
  98. Musacchio L, Califano D, Bartoletti M, et al. Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22). Br J Cancer. 2022; 127(8): 1479–1486.
    CrossRefPubMed
  99. Gershenson DM, Miller A, Brady WE, et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022; 399(10324): 541–553.
    CrossRefPubMed
  100. Grisham RN, Vergote I, Banerjee S, et al. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020; 38(32): 3753–3762.
    CrossRefPubMed
  101. Gershenson DM, Bodurka DC, Coleman RL, et al. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017; 35(10): 1103–1111.
    CrossRefPubMed
  102. Lago V, Minig L, Fotopoulou C. Incidence of Lymph Node Metastases in Apparent Early-Stage Low-Grade Epithelial Ovarian Cancer: A Comprehensive Review. Int J Gynecol Cancer. 2016; 26(8): 1407–1414.
    CrossRefPubMed
  103. Viveros-Carreño D, Rodriguez J, Pareja R. Incidence of lymph node metastasis in early-stage low-grade serous ovarian cancer: a systematic review. Int J Gynecol Cancer. 2022; 32(10): 1283–1288.
    CrossRefPubMed
  104. Montero-Macías R, Segura-Sampedro JJ, Rigolet P, et al. The Role of Systematic Lymphadenectomy in Low-Grade Serous Ovarian Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024; 16(5).
    CrossRefPubMed
  105. Dalton HJ, Fleming ND, Sun CC, et al. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Gynecol Oncol. 2017; 145(1): 37–40.
    CrossRefPubMed
  106. Bogani G, Tagliabue E, Ditto A, et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. Gynecol Oncol. 2017; 147(1): 61–65.
    CrossRefPubMed
  107. Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010; 102(13): 982–987.
    CrossRefPubMed
  108. Matsuo K, Huang Y, Matsuzaki S, et al. Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. JAMA Oncol. 2020; 6(7): 1110–1113.
    CrossRefPubMed
  109. Ditto A, Bogani G, Martinelli F, et al. Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery. J Minim Invasive Gynecol. 2017; 24(1): 98–102.
    CrossRefPubMed
  110. Grabowski JP, Harter P, Buhrmann C, et al. Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol. 2012; 21(1): 31–35.
    CrossRefPubMed
  111. Bentivegna E, Gouy S, Maulard A, et al. Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues. Ann Oncol. 2016; 27(11): 1994–2004.
    CrossRefPubMed
  112. Fruscio R, Ceppi L, Corso S, et al. Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. Br J Cancer. 2016; 115(6): 641–648.
    CrossRefPubMed
  113. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm 1, European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003; 95(2): 105–112.
    PubMed
  114. Collinson F, Qian W, Fossati R, et al. ICON1 collaborators. Optimal treatment of early-stage ovarian cancer. Ann Oncol. 2014; 25(6): 1165–1171.
    CrossRefPubMed
  115. Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev. 2012; 3(3): CD004706.
    CrossRefPubMed
  116. Bell J, Brady MF, Young RC, et al. Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 102(3): 432–439.
    CrossRefPubMed
  117. Sherman ME, Piedmonte M, Mai PL, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014; 32(29): 3275–3283.
    CrossRefPubMed
  118. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009; 22(9): 1133–1138.
    CrossRefPubMed
  119. Rabban JT, Garg K, Crawford B, et al. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014; 38(6): 729–742.
    CrossRefPubMed
  120. Reitsma W, de Bock GH, Oosterwijk JC, et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer. 2013; 49(1): 132–141.
    CrossRefPubMed
  121. Van der Hoeven NMA, Van Wijk K, Bonfrer SE, et al. Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review. Clin Oncol (R Coll Radiol). 2018; 30(8): 463–471.
    CrossRefPubMed
  122. Ruel-Laliberté J, Kasasni SM, Oprea D, et al. Outcome and Management of Serous Tubal Intraepithelial Carcinoma Following Opportunistic Salpingectomy: Systematic Review and Meta-Analysis. J Obstet Gynaecol Can. 2022; 44(11): 1174–1180.
    CrossRefPubMed
  123. Trimbos B, Timmers P, Pecorelli S, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst. 2010; 102(13): 982–987.
    CrossRefPubMed
  124. Matsuo K, Machida H, Mariani A, et al. Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. J Gynecol Oncol. 2018; 29(5): e69.
    CrossRefPubMed
  125. Yao G, Jin X. Impact of Lymphadenectomy on Outcomes of Early-Stage Ovarian Cancer: A Systematic Review and Meta-Analysis. Front Surg. 2021; 8: 682348.
    CrossRefPubMed
  126. Bizzarri N, du Bois A, Fruscio R, et al. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer? Gynecol Oncol. 2021; 160(1): 56–63.
    CrossRefPubMed
  127. Gouy S, Saidani M, Maulard A, et al. Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types. Gynecol Oncol Rep. 2017; 22: 21–25.
    CrossRefPubMed
  128. Muyldermans K, Moerman Ph, Amant F, et al. Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. Eur J Cancer. 2013; 49(7): 1600–1608.
    CrossRefPubMed
  129. Lin JE, Seo S, Kushner DM, et al. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013; 208(1): 46.e1–46.e4.
    CrossRefPubMed
  130. Ozcan A, Töz E, Turan V, et al. Should we remove the normal-looking appendix during operations for borderline mucinous ovarian neoplasms?: A retrospective study of 129 cases. Int J Surg. 2015; 18: 99–103.
    CrossRefPubMed
  131. Michel E, Mamguem Kamga A, Amet A, et al. Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d'Or Registry of Gynecological Cancers from 1998 to 2015. Bull Cancer. 2023; 110(4): 352–359.
    CrossRefPubMed
  132. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm 1, European Organisation for Research and Treatment of Cancer Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003; 95(2): 105–112.
    PubMed
  133. Trimbos JB, Vergote I, Bolis G, et al. Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst. 2003; 95(2): 113–125.
    CrossRefPubMed
  134. Perren TJ, Swart AM, Pfisterer J, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26): 2484–2496.
    CrossRefPubMed
  135. Matanes E, Volodarsky-Perel A, Eisenberg N, et al. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021; 28(5): 947–956.
    CrossRefPubMed
  136. Palmqvist C, Staf C, Mateoiu C, et al. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. Gynecol Oncol. 2020; 159(2): 409–417.
    CrossRefPubMed
  137. Timmermans M, Schuurman MS, Ho VKY, et al. Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery. Gynecol Oncol. 2018; 148(1): 56–61.
    CrossRefPubMed
  138. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009; 115(6): 1234–1244.
    CrossRefPubMed
  139. Stuart GCE, Kitchener H, Bacon M, et al. participants of 4th Ovarian Cancer Consensus Conference (OCCC), Gynecologic Cancer Intergroup. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011; 21(4): 750–755.
    CrossRefPubMed
  140. Gauci PA, Deluche E, Azais H, et al. Surgical management of patients with advanced ovarian cancer: Results of a French National Survey. J Gynecol Obstet Hum Reprod. 2022; 51(9): 102463.
    CrossRefPubMed
  141. Vergote I, Tropé CG, Amant F, et al. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10): 943–953.
    CrossRefPubMed
  142. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990): 249–257.
    CrossRefPubMed
  143. Coleridge SL, Bryant A, Kehoe S, et al. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021; 7(7): CD005343.
    CrossRefPubMed
  144. Rosendahl M, Harter P, Bjørn SF, et al. Specific Regions, Rather than the Entire Peritoneal Carcinosis Index, are Predictive of Complete Resection and Survival in Advanced Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2018; 28(2): 316–322.
    CrossRefPubMed
  145. Fuso L, Ferrero A, Vietti E, et al. Development of a preoperative computed tomography score for the management of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2019; 29(3): 599–604.
    CrossRefPubMed
  146. Michielsen KLM, Vergote I, Dresen R, et al. Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study. Br J Radiol. 2016; 89(1067): 20160468.
    CrossRefPubMed
  147. Michielsen K, Dresen R, Vanslembrouck R, et al. Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer. Eur J Cancer. 2017; 83: 88–98.
    CrossRefPubMed
  148. Engbersen MP, Van' T Sant I, Lok C, et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol. 2019; 114: 146–151.
    CrossRefPubMed
  149. Khiewvan B, Torigian DA, Emamzadehfard S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017; 44(6): 1079–1091.
    CrossRefPubMed
  150. van de Vrie R, Rutten MJ, Asseler JD, et al. Laparoscopy for diagnosing resectability of disease in women with advanced ovarian cancer. Cochrane Database Syst Rev. 2019; 3(3): CD009786.
    CrossRefPubMed
  151. Fagotti A, Ferrandina G, Fanfani F, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol. 2006; 13(8): 1156–1161.
    CrossRefPubMed
  152. Hall M, Savvatis K, Nixon K, et al. Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. Ann Surg Oncol. 2019; 26(9): 2943–2951.
    CrossRefPubMed
  153. Sundar S, Cummins C, Kumar S, et al. Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. BJOG. 2022; 129(7): 1122–1132.
    CrossRefPubMed
  154. Bryant A, Hiu S, Kunonga PT, et al. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst Rev. 2022; 9(9): CD015048.
    CrossRefPubMed
  155. Harter P, Sehouli J, Lorusso D, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med. 2019; 380(9): 822–832.
    CrossRefPubMed
  156. Classe JM, Campion L, Lecuru F, et al. Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial. J Clin Oncol. 2024; 42(17_suppl): LBA5505–LBA5505.
    CrossRef
  157. Wimberger P, Wehling M, Lehmann N, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol. 2010; 17(6): 1642–1648.
    CrossRefPubMed
  158. Winter WE, Maxwell GL, Tian C, et al. Gynecologic Oncology Group. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008; 26(1): 83–89.
    CrossRefPubMed
  159. Luna-Abanto J, García Ruiz L, Laura Martinez J, et al. Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer. J Gynecol Surg. 2020; 36(2): 70–75.
    CrossRefPubMed
  160. Wu CX, Chen ML, Zhang H, et al. Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis. Front Oncol. 2021; 11: 793024.
    CrossRefPubMed
  161. Kapnick SJ, Griffiths CT, Finkler NJ. Occult pleural involvement in stage III ovarian carcinoma: role of diaphragm resection. Gynecol Oncol. 1990; 39(2): 135–138.
    CrossRefPubMed
  162. Aletti GD, Dowdy SC, Podratz KC, et al. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol. 2006; 100(2): 283–287.
    CrossRefPubMed
  163. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 2001; 82(3): 435–441.
    CrossRefPubMed
  164. Silver DF. Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2004; 95(2): 384–387.
    CrossRefPubMed
  165. Juretzka MM, Horton FR, Abu-Rustum NR, et al. Full-thickness diaphragmatic resection for stage IV ovarian carcinoma using the EndoGIA stapling device followed by diaphragmatic reconstruction using a Gore-tex graft: a case report and review of the literature. Gynecol Oncol. 2006; 100(3): 618–620.
    CrossRefPubMed
  166. Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007; 107(1): 99–106.
    CrossRefPubMed
  167. Aletti GD, Dowdy SC, Podratz KC, et al. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007; 197(6): 676.e1–676.e7.
    CrossRefPubMed
  168. Fotopoulou C, Concin N, Planchamp F, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020; 30(4): 436–440.
    CrossRefPubMed
  169. Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. Int J Gynecol Cancer. 2016; 26(7): 1354–1363.
    CrossRefPubMed
  170. Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016; 140(3): 457–462.
    CrossRefPubMed
  171. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012; 124(1): 10–14.
    CrossRefPubMed
  172. Narasimhulu DM, Fagotti A, Scambia G, et al. Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancer. Int J Gynecol Cancer. 2023; 33(1): 83–88.
    CrossRefPubMed
  173. Fischerova D, Pinto P, Burgetova A, et al. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole‐body diffusion‐weighted MRI (ISAAC study). Ultrasound Obstet Gynecol. 2022; 59(2): 248–262.
    CrossRefPubMed
  174. Abdalla Ahmed S, Abou-Taleb H, Ali N, et al. Accuracy of radiologic- laparoscopic peritoneal carcinomatosis categorization in the prediction of surgical outcome. Br J Radiol. 2019; 92(1100): 20190163.
    CrossRefPubMed
  175. Fagotti A, Vizzielli G, Fanfani F, et al. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience. Gynecol Oncol. 2013; 131(2): 341–346.
    CrossRefPubMed
  176. Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000; 88(2): 389–397, doi: 10.1002/(sici)1097-0142(20000115)88:2<389::aid-cncr21>3.0.co;2-w.
    PubMed
  177. Bristow RE, del Carmen MG, Kaufman HS, et al. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg. 2003; 197(4): 565–574.
    CrossRefPubMed
  178. Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005; 99(3): 608–614.
    CrossRefPubMed
  179. Salani R, Zahurak ML, Santillan A, et al. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007; 107(3): 495–499.
    CrossRefPubMed
  180. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006; 103(3): 1083–1090.
    CrossRefPubMed
  181. Scholz HS, Tasdemir H, Hunlich T, et al. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol. 2007; 106(3): 591–595.
    CrossRefPubMed
  182. Eisenkop SM, Spirtos NM, Lin WCM. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol. 2006; 100(2): 344–348.
    CrossRefPubMed
  183. Sun H, Bi X, Cao D, et al. Splenectomy during cytoreductive surgery in epithelial ovarian cancer. Cancer Manag Res. 2018; 10: 3473–3482.
    CrossRefPubMed
  184. Acs M, Piso P, Prader S. Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review. Anticancer Res. 2022; 42(1): 13–24.
    CrossRefPubMed
  185. Kengsakul M, Nieuwenhuyzen-de Boer GM, Bijleveld AHJ, et al. Survival in Advanced-Stage Epithelial Ovarian Cancer Patients with Cardiophrenic Lymphadenopathy Who Underwent Cytoreductive Surgery: A Systematic Review and Meta-Analysis. Cancers (Basel). 2021; 13(19).
    CrossRefPubMed
  186. Harter P, Sehouli J, Vergote I, et al. DESKTOP III Investigators. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2021; 385(23): 2123–2131.
    CrossRefPubMed
  187. Baek MH, Park EY, Ha HIn, et al. Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis. J Clin Oncol. 2022; 40(15): 1659–1670.
    CrossRefPubMed
  188. Marchetti C, Fagotti A, Tombolini V, et al. The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2021; 28(6): 3258–3263.
    CrossRefPubMed
  189. Ding T, Tang D, Xi M. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis. J Ovarian Res. 2021; 14(1): 93.
    CrossRefPubMed
  190. Goldberg RM, Kim SR, Fazelzad R, et al. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis. Gynecol Oncol. 2022; 164(1): 212–220.
    CrossRefPubMed
  191. Miccò M, Sbarra M, Gui B, et al. Prognostic CT findings of malignant bowel obstruction in patients with advanced ovarian cancer. Tumori. 2020; 106(2): 149–154.
    CrossRefPubMed
  192. Li Z, Zhang L, Liu X, et al. Diagnostic utility of CT for small bowel obstruction: Systematic review and meta-analysis. PLoS One. 2019; 14(12): e0226740.
    CrossRefPubMed
  193. Krouse RS, Anderson GL, Arnold KB, et al. Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Lancet Gastroenterol Hepatol. 2023; 8(10): 908–918.
    CrossRefPubMed
  194. Bozzetti F, Gavazzi C, Miceli R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr. 2000; 24(1): 7–14.
    CrossRefPubMed
  195. Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. Perioperative total parenteral nutrition in surgical patients. N Engl J Med. 1991; 325(8): 525–532.
    CrossRefPubMed
  196. Parmar KL, Zammit M, Smith A, et al. Greater Manchester and Cheshire Colorectal Cancer Network. A prospective audit of early stoma complications in colorectal cancer treatment throughout the Greater Manchester and Cheshire colorectal cancer network. Colorectal Dis. 2011; 13(8): 935–938.
    CrossRefPubMed
  197. Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017; 9: 115–130.
    CrossRefPubMed
  198. Stukan M, Leśniewski-Kmak K, Wróblewska M, et al. Management of symptomatic ascites and post-operative lymphocysts with an easy-to-use, patient-controlled, vascular catheter. Gynecol Oncol. 2015; 136(3): 466–471.
    CrossRefPubMed
  199. Antony VB, Loddenkemper R, Astoul P, et al. Management of malignant pleural effusions. Eur Respir J. 2001; 18(2): 402–419.
    CrossRefPubMed
  200. Boerner T, Filippova OT, Chi AJ, et al. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecol Oncol. 2020; 159(1): 66–71.
    CrossRefPubMed
  201. Nasser S, Kyrgiou M, Krell J, et al. A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries. Ann Surg Oncol. 2017; 24(12): 3700–3705.
    CrossRefPubMed
  202. Cianci S, Fedele C, Vizzielli G, et al. Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial - DRAGON. Gynecol Oncol. 2022; 164(2): 271–277.
    CrossRefPubMed
  203. Eisenhauer EL, D'Angelica MI, Abu-Rustum NR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. Gynecol Oncol. 2006; 103(3): 871–877.
    CrossRefPubMed
  204. Kahl A, du Bois A, Harter P, et al. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer. Ann Surg Oncol. 2017; 24(12): 3692–3699.
    CrossRefPubMed
  205. Narasimhulu DM, Kumar A, Weaver AL, et al. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2019; 155(1): 58–62.
    CrossRefPubMed
  206. Narasimhulu DM, Thannickal A, Kumar A, et al. Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy. Gynecol Oncol. 2021; 160(3): 681–687.
    CrossRefPubMed
  207. Miralpeix E, Sole-Sedeno JM, Rodriguez-Cosmen C, et al. Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study. World J Surg Oncol. 2022; 20(1): 46.
    CrossRefPubMed
  208. Diaz-Feijoo B, Agusti-Garcia N, Sebio R, et al. Feasibility of a Multimodal Prehabilitation Programme in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer: A Pilot Study. Cancers (Basel). 2022; 14(7).
    CrossRefPubMed
  209. Dhanis J, Keidan N, Blake D, et al. Prehabilitation to Improve Outcomes of Patients with Gynaecological Cancer: A New Window of Opportunity? Cancers (Basel). 2022; 14(14).
    CrossRefPubMed
  210. Goins EC, Weber JM, Truong T, et al. Malnutrition as a risk factor for post-operative morbidity in gynecologic cancer: Analysis using a national surgical outcomes database. Gynecol Oncol. 2022; 165(2): 309–316.
    CrossRefPubMed
  211. Yim GaW, Eoh KJ, Kim SW, et al. Malnutrition Identified by the Nutritional Risk Index and Poor Prognosis in Advanced Epithelial Ovarian Carcinoma. Nutr Cancer. 2016; 68(5): 772–779.
    CrossRefPubMed
  212. Cederholm T, Jensen GL, Correia MI, et al. GLIM Core Leadership Committee, GLIM Working Group. GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. J Cachexia Sarcopenia Muscle. 2019; 10(1): 207–217.
    CrossRefPubMed
  213. Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020; 11(2): 366–380.
    CrossRefPubMed
  214. Billson HA, Holland C, Curwell J, et al. Perioperative nutrition interventions for women with ovarian cancer. Cochrane Database Syst Rev. 2013; 2013(9): CD009884.
    CrossRefPubMed
  215. Weimann A, Braga M, Carli F, et al. ESPEN practical guideline: Clinical nutrition in surgery. Clin Nutr. 2021; 40(7): 4745–4761.
    CrossRefPubMed
  216. Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr. 2021; 40(5): 2898–2913.
    CrossRefPubMed
  217. Sasamoto N, Wang T, Townsend MK, et al. Pre-diagnosis and post-diagnosis dietary patterns and survival in women with ovarian cancer. Br J Cancer. 2022; 127(6): 1097–1105.
    CrossRefPubMed
  218. Playdon MC, Nagle CM, Ibiebele TI, et al. Pre-diagnosis diet and survival after a diagnosis of ovarian cancer. Br J Cancer. 2017; 116(12): 1627–1637.
    CrossRefPubMed
  219. Hurtado-Barroso S, Trius-Soler M, Lamuela-Raventós RM, et al. Vegetable and Fruit Consumption and Prognosis Among Cancer Survivors: A Systematic Review and Meta-Analysis of Cohort Studies. Adv Nutr. 2020; 11(6): 1569–1582.
    CrossRefPubMed
  220. Ubachs J, Ziemons J, Minis-Rutten IJG, et al. Sarcopenia and ovarian cancer survival: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019; 10(6): 1165–1174.
    CrossRefPubMed
  221. Jin Y, Ma X, Yang Z, et al. Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis. J Cachexia Sarcopenia Muscle. 2023; 14(2): 697–705.
    CrossRefPubMed
  222. Ackermans LL, Rabou J, Basrai M, et al. Screening, diagnosis and monitoring of sarcopenia: When to use which tool? Clin Nutr ESPEN. 2022; 48: 36–44.
    CrossRefPubMed
  223. McSharry V, Glennon K, Mullee A, et al. The impact of body composition on treatment in ovarian cancer: a current insight. Expert Rev Clin Pharmacol. 2021; 14(9): 1065–1074.
    CrossRefPubMed
  224. Levett DZH, Jack S, Swart M, et al. Perioperative Exercise Testing and Training Society (POETTS). Perioperative cardiopulmonary exercise testing (CPET): consensus clinical guidelines on indications, organization, conduct, and physiological interpretation. Br J Anaesth. 2018; 120(3): 484–500.
    CrossRefPubMed
  225. Sinclair RCF, Batterham AM, Davies S, et al. Validity of the 6 min walk test in prediction of the anaerobic threshold before major non-cardiac surgery. Br J Anaesth. 2012; 108(1): 30–35.
    CrossRefPubMed
  226. Lee L, Schwartzman K, Carli F, et al. The association of the distance walked in 6 min with pre-operative peak oxygen consumption and complications 1 month after colorectal resection. Anaesthesia. 2013; 68(8): 811–816.
    CrossRefPubMed
  227. Waterland JL, McCourt O, Edbrooke L, et al. Efficacy of Prehabilitation Including Exercise on Postoperative Outcomes Following Abdominal Cancer Surgery: A Systematic Review and Meta-Analysis. Front Surg. 2021; 8: 628848.
    CrossRefPubMed
  228. Watts S, Prescott P, Mason J, et al. Depression and anxiety in ovarian cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open. 2015; 5(11): e007618.
    CrossRefPubMed
  229. Barberan-Garcia A, Cano I, Bongers BC, et al. Digital Support to Multimodal Community-Based Prehabilitation: Looking for Optimization of Health Value Generation. Front Oncol. 2021; 11: 662013.
    CrossRefPubMed
  230. Díaz-Feijoo B, Agusti N, Sebio R, et al. A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE). Int J Gynecol Cancer. 2022; 32(11): 1463–1468.
    CrossRefPubMed
  231. Groes-Kofoed N, Hasselgren E, Björne H, et al. Surgery performed later in the week is associated with inferior survival in advanced ovarian cancer. Acta Oncol. 2021; 60(11): 1513–1519.
    CrossRefPubMed
  232. Palsdottir K, Joneborg U, Hasselgren E, et al. Surgery performed later in the week is associated with failure to achieve complete radical surgical resection in advanced ovarian cancer. Acta Oncol. 2020; 59(7): 760–765.
    CrossRefPubMed
  233. Jessen MK, Vallentin MF, Holmberg MJ, et al. Goal-directed haemodynamic therapy during general anaesthesia for noncardiac surgery: a systematic review and meta-analysis. Br J Anaesth. 2022; 128(3): 416–433.
    CrossRefPubMed
  234. Kucewicz-Czech E, Krzych Ł, Ligowski M. Optymalizacja funkcji układu krążenia w okresie okołooperacyjnym u chorych poddawanych operacjom niekardiochirurgicznym — stanowisko Sekcji Kardiotorakoanestezjologii Polskiego Towarzystwa Anestezjologii i Intensywnej Terapii. Część 1. Anestezjologia Intensywna Terapia. 2017; 49(1): 6–15.
    CrossRef
  235. Kucewicz-Czech E, Krzych Ł, Ligowski M. Optymalizacja funkcji układu krążenia w okresie okołooperacyjnym u chorych poddawanych operacjom niekardiochirurgicznym — stanowisko Sekcji Kardiotorakoanestezjologii Polskiego Towarzystwa Anestezjologii i Intensywnej Terapii. Część 2. Anestezjologia Intensywna Terapia. 2017; 49(1): 16–27.
    CrossRef
  236. Lundin ES, Johansson T, Zachrisson H, et al. Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study. Acta Obstet Gynecol Scand. 2014; 93(4): 335–344.
    CrossRefPubMed
  237. Heyns M, Knight P, Steve AK, et al. A Single Preoperative Dose of Tranexamic Acid Reduces Perioperative Blood Loss: A Meta-analysis. Ann Surg. 2021; 273(1): 75–81.
    CrossRefPubMed
  238. Devereaux PJ, Marcucci M, Painter TW, et al. POISE-3 Investigators. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med. 2022; 386(21): 1986–1997.
    CrossRefPubMed
  239. Agarwal R, Rajanbabu A, P V N, et al. A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer. Int J Gynecol Cancer. 2019; 29(3): 605–612.
    CrossRefPubMed
  240. Coleman R, Oza A, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106): 1949–1961.
    CrossRefPubMed
  241. Bisch SP, Jago CA, Kalogera E, et al. Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis. Gynecol Oncol. 2021; 161(1): 46–55.
    CrossRefPubMed
  242. Schneider S, Armbrust R, Spies C, et al. Prehabilitation programs and ERAS protocols in gynecological oncology: a comprehensive review. Arch Gynecol Obstet. 2020; 301(2): 315–326.
    CrossRefPubMed
  243. O'Neill AM, Calpin GG, Norris L, et al. The impact of enhanced recovery after gynaecological surgery: A systematic review and meta-analysis. Gynecol Oncol. 2023; 168: 8–16.
    CrossRefPubMed
  244. Pöpping DM, Elia N, Van Aken HK, et al. Impact of epidural analgesia on mortality and morbidity after surgery: systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2014; 259(6): 1056–1067.
    CrossRefPubMed
  245. Pöpping DM, Elia N, Marret E, et al. Protective effects of epidural analgesia on pulmonary complications after abdominal and thoracic surgery: a meta-analysis. Arch Surg. 2008; 143(10): 990–9; discussion 1000.
    CrossRefPubMed
  246. Guay J, Nishimori M, Kopp SL. Epidural Local Anesthetics Versus Opioid-Based Analgesic Regimens for Postoperative Gastrointestinal Paralysis, Vomiting, and Pain After Abdominal Surgery: A Cochrane Review. Anesth Analg. 2016; 123(6): 1591–1602.
    CrossRefPubMed
  247. Hung KC, Chu CC, Hsing CH, et al. Association between perioperative intravenous lidocaine and subjective quality of recovery: A meta-analysis of randomized controlled trials. J Clin Anesth. 2021; 75: 110521.
    CrossRefPubMed
  248. Rollins KE, Javanmard-Emamghissi H, Scott MJ, et al. The impact of peri-operative intravenous lidocaine on postoperative outcome after elective colorectal surgery: A meta-analysis of randomised controlled trials. Eur J Anaesthesiol. 2020; 37(8): 659–670.
    CrossRefPubMed
  249. Weibel S, Jelting Y, Pace NL, et al. Continuous intravenous perioperative lidocaine infusion for postoperative pain and recovery in adults. Cochrane Database Syst Rev. 2018; 6(6): CD009642.
    CrossRefPubMed
  250. Foo I, Macfarlane AJR, Srivastava D, et al. The use of intravenous lidocaine for postoperative pain and recovery: international consensus statement on efficacy and safety. Anaesthesia. 2021; 76(2): 238–250.
    CrossRefPubMed
  251. Doleman B, Heinink TP, Read DJ, et al. A systematic review and meta-regression analysis of prophylactic gabapentin for postoperative pain. Anaesthesia. 2015; 70(10): 1186–1204.
    CrossRefPubMed
  252. Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin: a combined systematic review and meta-analysis. Anesth Analg. 2012; 115(2): 428–442.
    CrossRefPubMed
  253. Madrid E, Urrútia G, Roqué i Figuls M, et al. Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults. Cochrane Database Syst Rev. 2016; 4(4): CD009016.
    CrossRefPubMed
  254. Balki I, Khan JS, Staibano P, et al. Effect of Perioperative Active Body Surface Warming Systems on Analgesic and Clinical Outcomes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesth Analg. 2020; 131(5): 1430–1443.
    CrossRefPubMed
  255. Grote R, Wetz AJ, Bräuer A, et al. Vorwärmung entsprechend der „S3 Leitlinie Vermeidung von unbeabsichtigter perioperativer Hypothermie 2014“. Anaesthesist. 2017; 67(1): 27–33.
    CrossRefPubMed
  256. Kaufner L, Niggemann P, Baum T, et al. Impact of brief prewarming on anesthesia-related core-temperature drop, hemodynamics, microperfusion and postoperative ventilation in cytoreductive surgery of ovarian cancer: a randomized trial. BMC Anesthesiol. 2019; 19(1): 161.
    CrossRefPubMed
  257. Yoo JH, Ok SiY, Kim SHo, et al. Efficacy of active forced air warming during induction of anesthesia to prevent inadvertent perioperative hypothermia in intraoperative warming patients: Comparison with passive warming, a randomized controlled trial. Medicine (Baltimore). 2021; 100(12): e25235.
    CrossRefPubMed
  258. Horn EP, Bein B, Broch O, et al. Warming before and after epidural block before general anaesthesia for major abdominal surgery prevents perioperative hypothermia: A randomised controlled trial. Eur J Anaesthesiol. 2016; 33(5): 334–340.
    CrossRefPubMed
  259. Andrzejowski J, Hoyle J, Eapen G, et al. Effect of prewarming on post-induction core temperature and the incidence of inadvertent perioperative hypothermia in patients undergoing general anaesthesia. Br J Anaesth. 2008; 101(5): 627–631.
    CrossRefPubMed
  260. Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21(17): 3194–3200.
    CrossRefPubMed
  261. Bookman MA. The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann Oncol. 2010; 21 Suppl 7: vii211–vii217.
    CrossRefPubMed
  262. Walker JL, Brady MF, Wenzel L, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2019; 37(16): 1380–1390.
    CrossRefPubMed
  263. Ngoi NYl, Syn NLx, Goh RM, et al. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. Cochrane Database Syst Rev. 2022; 2(2): CD012007.
    CrossRefPubMed
  264. Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2022; 23(7): 919–930.
    CrossRefPubMed
  265. Pignata S, Scambia G, Katsaros D, et al. Multicentre Italian Trials in Ovarian cancer (MITO-7), Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO), Mario Negri Gynecologic Oncology (MaNGO), European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10), Gynecologic Cancer InterGroup (GCIG) Investigators. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014; 15(4): 396–405.
    CrossRefPubMed
  266. Heilmann T, Pfisterer J, Hempel AM, et al. Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years. Gynecol Oncol. 2019; 153(3): 616–624.
    CrossRefPubMed
  267. Falandry C, Rousseau F, Mouret-Reynier MA, et al. Groupe d’Investigateurs Nationaux pour l’Étude des Cancers de l’Ovaire et du sein (GINECO). Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial. JAMA Oncol. 2021; 7(6): 853–861.
    CrossRefPubMed
  268. Pignata S, Scambia G, Savarese A, et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology. 2009; 76(1): 49–54.
    CrossRefPubMed
  269. Vasey PA, Jayson GC, Gordon A, et al. Scottish Gynaecological Cancer Trials Group. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22): 1682–1691.
    CrossRefPubMed
  270. Oza AM, Cook AD, Pfisterer J, et al. ICON7 trial investigators. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015; 16(8): 928–936.
    CrossRefPubMed
  271. Tewari KS, Burger RA, Enserro D, et al. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019; 37(26): 2317–2328.
    CrossRefPubMed
  272. Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26): 2495–2505.
    CrossRefPubMed
  273. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(12): 1721–1731.
    CrossRefPubMed
  274. DiSilvestro P, Banerjee S, Colombo N, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. Journal of Clinical Oncology. 2023; 41(3): 609–617.
    CrossRef
  275. González-Martín A, Pothuri B, Vergote I, et al. PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019; 381(25): 2391–2402.
    CrossRefPubMed
  276. González-Martín A, Pothuri B, Vergote I, et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023; 189: 112908.
    CrossRefPubMed
  277. Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024; 35(11): 981–992.
    CrossRefPubMed
  278. Ray-Coquard I, Pautier P, Pignata S, et al. PAOLA-1 Investigators. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. N Engl J Med. 2019; 381(25): 2416–2428.
    CrossRefPubMed
  279. Ray-Coquard I, Leary A, Pignata S, et al. PAOLA-1/ENGOT-ov25 investigators. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol. 2023; 34(8): 681–692.
    CrossRefPubMed
  280. Moore KN, Bookman M, Sehouli J, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021; 39(17): 1842–1855.
    CrossRefPubMed
  281. Monk BJ, Colombo N, Oza AM, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(9): 1275–1289.
    CrossRefPubMed
  282. Monk BJ, Oaknin A, O'Malley DM, et al. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Ann Oncol. 2024; 35: S1223–S1224.
    CrossRef
  283. Harter P, Trillsch F, Okamoto A, et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J Clin Oncol. 2023; 41(17_suppl): LBA5506–LBA5506.
    CrossRef
  284. Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006; 17(Suppl 5): v181–v187.
    CrossRefPubMed
  285. du Bois A, Luck HJ, Meier W, et al. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. Semin Oncol. 1997; 24(5 Suppl 15): S15-44–S15-52.
    PubMed
  286. Lim MC, Chang SJ, Park B, et al. HIPEC for Ovarian Cancer Collaborators. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. JAMA Surg. 2022; 157(5): 374–383.
    CrossRefPubMed
  287. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006; 103(3): 1070–1076.
    CrossRefPubMed
  288. Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26): 2473–2483.
    CrossRefPubMed
  289. Perren TJ, Swart AM, Pfisterer J, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26): 2484–2496.
    CrossRefPubMed
  290. Garcia Garcia Y, de Juan Ferré A, Mendiola C, et al. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2019; 29(6): 1050–1056.
    CrossRefPubMed
  291. Rouzier R, Gouy S, Selle F, et al. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur J Cancer. 2017; 70: 133–142.
    CrossRefPubMed
  292. Pfisterer J, Joly F, Kristensen G, et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol. 2023; 41(4): 893–902.
    CrossRefPubMed
  293. Capoluongo E, Ellison G, López-Guerrero JA, et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Semin Oncol. 2017; 44(3): 187–197.
    CrossRefPubMed
  294. You B, Purdy C, Copeland LJ, et al. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. J Clin Oncol. 2022; 40(34): 3965–3974.
    CrossRefPubMed
  295. You B, Robelin P, Tod M, et al. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clin Cancer Res. 2020; 26(17): 4625–4632.
    CrossRefPubMed
  296. Knickerbocker A, Kuchta K, Donaldson C, et al. Tissue is the issue: Chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC) (488). Gynecol Oncol. 2022; 166: S241–S242.
    CrossRef
  297. Lawson BC, Euscher ED, Bassett RL, et al. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant? Am J Surg Pathol. 2020; 44(2): 206–213.
    CrossRefPubMed
  298. González-Martín A, Desauw C, Heitz F, et al. PAOLA1/ENGOT-ov25 investigators. Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial. Eur J Cancer. 2022; 174: 221–231.
    CrossRefPubMed
  299. Harter P, Mouret-Reynier MA, Pignata S, et al. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Gynecol Oncol. 2022; 164(2): 254–264.
    CrossRefPubMed
  300. Wilson MK, Pujade-Lauraine E, Aoki D, et al. participants of the Fifth Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017; 28(4): 727–732.
    CrossRefPubMed
  301. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30(17): 2039–2045.
    CrossRefPubMed
  302. Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017; 18(6): 779–791.
    CrossRefPubMed
  303. Pfisterer J, Plante M, Vergote I, et al. AGO-OVAR, NCIC CTG, EORTC GCG. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24(29): 4699–4707.
    CrossRefPubMed
  304. Parmar MKB, Ledermann JA, Colombo N, et al. ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361(9375): 2099–2106.
    CrossRefPubMed
  305. Liu Y, Huang Y, Li J, et al. A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. Front Pharmacol. 2022; 13: 1010626.
    CrossRefPubMed
  306. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010; 28(20): 3323–3329.
    CrossRefPubMed
  307. Vetter MH, Khan A, Backes FJ, et al. Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. Gynecol Oncol. 2019; 152(2): 316–321.
    CrossRefPubMed
  308. Gordon AN, Tonda M, Sun S, et al. Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004; 95(1): 1–8.
    CrossRefPubMed
  309. Monk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020; 156(3): 535–544.
    CrossRefPubMed
  310. Pfisterer J, Shannon C, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020; 21(5): 699–709.
    CrossRefPubMed
  311. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008; 26(6): 890–896.
    CrossRefPubMed
  312. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007; 25(19): 2811–2818.
    CrossRefPubMed
  313. Markman M, Blessing J, Rubin SC, et al. Gynecologic Oncology Group. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006; 101(3): 436–440.
    CrossRefPubMed
  314. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13): 1302–1308.
    CrossRefPubMed
  315. Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol. 2011; 29(2): 242–248.
    CrossRefPubMed
  316. Moore KN, Angelergues A, Konecny GE, et al. Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023; 389(23): 2162–2174.
    CrossRefPubMed
  317. Filis P, Mauri D, Markozannes G, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022; 7(5): 100586.
    CrossRefPubMed
  318. Cianci S, Riemma G, Ronsini C, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: systematic review and meta-analysis. Gland Surg. 2020; 9(4): 1140–1148.
    CrossRefPubMed
  319. Classe JM, Meeus P, Hudry D, et al. UNICANCER/CHIPOR Investigators. Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2024; 25(12): 1551–1562.
    CrossRefPubMed
  320. Taliento C, Restaino S, Scutiero G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review. Eur J Surg Oncol. 2023; 49(12): 107250.
    CrossRefPubMed
  321. Colombo N, Sessa C, du Bo, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019; 30(5): 672–705.
    CrossRefPubMed
  322. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15): 1382–1392.
    CrossRefPubMed
  323. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15(8): 852–861.
    CrossRefPubMed
  324. Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016; 17(11): 1579–1589.
    CrossRefPubMed
  325. Mirza MR, Monk BJ, Herrstedt J, et al. ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22): 2154–2164.
    CrossRefPubMed
  326. Hammoud D, Gallagher KM, Haddad PA. 826P Comparative efficacy of first-line maintenance PARP inhibitors (PARPI) in advanced ovarian cancer (OC): A network meta-analysis. Ann Oncol. 2020; 31: S623.
    CrossRef
  327. Maiorano BA, Maiorano MF, Lorusso D, et al. Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2022; 32(11): 1410–1418.
    CrossRefPubMed
  328. Zhang C, Zhao W. The efficacy and safety of angiogenesis inhibitors for recurrent ovarian cancer: a meta‑analysis. J Ovarian Res. 2022; 15(1): 99.
    CrossRefPubMed
  329. Pignata S, Lorusso D, Joly F, et al. MITO16b/MANGO–OV2/ENGOT–ov17 Investigators. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. Lancet Oncol. 2021; 22(2): 267–276.
    CrossRefPubMed
  330. Khoja L, Nolan K, Mekki R, et al. Improved Survival from Ovarian Cancer in Patients Treated in Phase III Trial Active Cancer Centres in the UK. Clin Oncol (R Coll Radiol). 2016; 28(12): 760–765.
    CrossRefPubMed
  331. Spiliopoulou P, Hinsley S, McNeish IA, et al. Metronomic oral cyclophosphamide in relapsed ovarian cancer. Int J Gynecol Cancer. 2021; 31(7): 1037–1044.
    CrossRefPubMed
  332. Zivanovic O, Chi DS, Zhou Q, et al. Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. J Clin Oncol. 2021; 39(23): 2594–2604.
    CrossRefPubMed
  333. Mohammad A, Hor M, Baradeiya AM, et al. Is Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) Effective in Ovarian Cancer With Peritoneal Metastasis? Cureus. 2022; 14(8): e27837.
    CrossRefPubMed
  334. Hasson SP, Ray-Coquard I, Marth C, et al. Surgery and HIPEC in relapse for all patients with ovarian cancer? ESMO Open. 2023; 8(6): 102052.
    CrossRefPubMed
  335. Geurts SME, de Vegt F, van Altena AM, et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2011; 21(5): 837–845.
    CrossRefPubMed
  336. Geurts SME, van Altena AM, de Vegt F, et al. No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study. Int J Gynecol Cancer. 2011; 21(4): 647–653.
    CrossRefPubMed
  337. Bois ADu, Vergote I, Ferron G, et al. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017; 35(15_suppl): 5501–5501.
    CrossRef
  338. Woopen H, Sehouli J, Davis A, et al. GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee. Cancer Treat Rev. 2022; 107: 102396.
    CrossRefPubMed
  339. Moss E, Taylor A, Andreou A, et al. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024. Eur J Obstet Gynecol Reprod Biol. 2024; 300: 69–123.
    CrossRefPubMed
  340. Lavie O, Chetrit A, Novikov I, et al. National Israeli Study of Ovarian Cancer. Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer. Gynecol Oncol. 2019; 153(2): 320–325.
    CrossRefPubMed
  341. Temkin SM, Mallen A, Bellavance E, et al. The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions. Cancer. 2019; 125(4): 499–514.
    CrossRefPubMed
  342. Gernier F, Gompel A, Rousset-Jablonski C, et al. Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study. Gynecol Oncol. 2021; 163(3): 598–604.
    CrossRefPubMed
  343. Saeaib N, Peeyananjarassri K, Liabsuetrakul T, et al. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst Rev. 2020; 1(1): CD012559.
    CrossRefPubMed
  344. Li D, Ding CY, Qiu LH. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol Oncol. 2015; 139(2): 355–362.
    CrossRefPubMed
  345. Pergialiotis V, Pitsouni E, Prodromidou A, et al. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016; 23(3): 335–342.
    CrossRefPubMed
  346. Sinno AK, Pinkerton J, Febbraro T, et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol Oncol. 2020; 157(2): 303–306.
    CrossRefPubMed
  347. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. Pathol Oncol Res. 2020; 26(1): 63–78.
    CrossRefPubMed
  348. Rousset-Jablonski C, Selle F, Adda-Herzog E, et al. Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO). Bull Cancer. 2018; 105(3): 299–314.
    CrossRefPubMed
  349. Na R, Jordan SJ, DeFazio A, et al. OPAL Study Group. Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in Australia. Int J Cancer. 2025; 156(2): 280–292.
    CrossRefPubMed
  350. Sénéchal C, Akladios C, Bendifallah S, et al. Surveillance après traitement initial d’une tumeur épithéliale de l’ovaire, place du traitement hormonal de la ménopause et de la contraception. Article rédigé sur la base de la recommandation nationale de bonnes pratiques cliniques en cancérologie intitulée « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY sous l’égide du CNGOF et labellisée par l’INCa. Gynecol Obstet Fertil Senol. 2019; 47(2): 250–262.
    CrossRefPubMed
  351. Donohoe F, O'Meara Y, Roberts A, et al. Using menopausal hormone therapy after a cancer diagnosis in Ireland. Ir J Med Sci. 2023; 192(1): 45–55.
    CrossRefPubMed
  352. Power L, Lefas G, Lambert P, et al. Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival. Obstet Gynecol. 2016; 127(5): 837–847.
    CrossRefPubMed
  353. Eeles RA, Morden JP, Gore M, et al. Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. J Clin Oncol. 2015; 33(35): 4138–4144.
    CrossRefPubMed

Informacje o plikach cookie

Niezbędne pliki cookie

Zawsze aktywne

Te pliki cookie są niezbędne do prawidłowego wyświetlania i działania strony internetowej. Zablokowanie ich może spowodować nieprawidłowe działanie strony.

Analityczne pliki cookie

W ramach naszej strony internetowej korzystamy z narzędzi analitycznych, takich jak Google Analytics, które umożliwiają nam weryfikację ruchu na stronie internetowej. Narzędzia te mogą wymagać użycia plików cookie.

Społecznościowe pliki cookie

Są to pliki cookie powiązane z portalami społecznościowymi, z których korzystamy. Zaakceptowanie ich pozwoli na powiązanie Twojej wizyty na stronie z naszymi profilami w mediach społecznościowych.

Marketingowe pliki cookie

Są to pliki cookie odpowiedzialne za prowadzenie działań reklamowych i marketingowych - zgoda na ich wykorzystanie pozwoli nam kierować do Ciebie reklamy, bazujące na podstawie Twoich wcześniejszych aktywności w ramach naszej stronie internetowej.

Copyright © 2023-2025 Via Medica Regulamin Polityka cookies Polityka prywatności Nota prawna

Eksport do Mediów Społecznościowych

Facebook X LinkedIn Share
More…
Dodaj do koszyka: 95,00 PLN
Pobierz cytowanie
CIT